ArticleBMC microbiology2026
Occurrence of antimicrobial-resistant, extended-spectrum beta-lactamase and carbapenemase-producing bacterial isolates from intensive care unit environment in two hospitals of Ethiopia.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntensive care unit environments are a critical reservoir of antimicrobial-resistant bacterial species and facilitate the transmission of nosocomial infections. This unit harbors multidrug-resistant organisms, thereby complicating the management of infectious diseases within clinical settings, particularly in resource-limited countries. This study, therefore, aimed to determine the occurrence and antimicrobial resistance profiles of bacteria, including Extended-spectrum beta-lactamase- and Carbapenemase-producing isolates, in the intensive care units of two hospitals in Addis Ababa, Ethiopia.
methodsA repeated cross-sectional study was conducted in Addis Ababa, Ethiopia, from July 2024 to April 2025. A total of 239 swab samples were collected from adult and neonatal intensive care unit environments during both the dry and rainy seasons. Samples were collected and processed aseptically. Bacterial identification and antimicrobial susceptibility testing were performed according to CLSI guidelines.
resultsFrom the total samples collected, 162/239 (67.8%) bacterial isolates were recovered from the Intensive Care Unit environment. Klebsiella pneumoniae 22/162 (13.6%) and Pseudomonas aeruginosa 21/162 (13%) were the most frequently isolated bacterial species. All P. aeruginosa were resistant to ceftazidime, while 19/22 (86.3%) and 18/22 (81.8%) of K. pneumoniae were resistant to cefuroxime and cefotaxime, respectively. All S.haemolyticus were also resistant to penicillin, and 8/12 (66.7%) of Enterococcus spp were resistant to erythromycin. Multidrug-resistant bacteria were seen in 89/150 (59.3%) of isolates. The highest multidrug resistance rate was obtained for Pseudomonas aeruginosa 18/21 (85.7%), followed by Klebsiella pneumoniae 16/22 (72.7%) and Acinetobacter spp 8/11 (72.7%). Extended-spectrum β-lactamase-producing isolates accounted for 23/105 (21.9%), and Carbapenemase-producers comprised 10/105 (9.5%).
conclusionThe environments within intensive care units are conducive to the proliferation of multidrug-resistant microorganisms, encompassing bacterial isolates that produce extended-spectrum beta-lactamases and carbapenemases, thereby complicating the management of infectious diseases. Consequently, it is crucial to address the issue of antimicrobial resistance in this critical setting to mitigate the incidence and dissemination of resistant bacteria, which may lead to the emergence of nosocomial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.